Globus Medical - Class A opened lower at $75.30, compared with its previous close of $75.39. In the last trading session, the stock traded between $73.20 and $75.45. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Globus Medical - Class A is now worth
$ 98.20
Resulting in a loss of
$ 1.80 (1.80%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
60%
Hold
40%
Sell
0%
Markets Today
Today's Change
$-3.09 (-4.10%)
Day High
$75.45
Day Low
$73.20
Day Open
$75.30
Prev Close
$75.39
Volume
9,88,512
1W Return
-16.97%
1M Return
-5.20%
3M Return
-15.10%
6M Return
-5.72%
1Y Return
-14.89%
Fundamentals
Market Cap ($ Mn)
7,956
PE Ratio
21.27
PB Ratio
2.34
PEG Ratio
1.27
ROE
12.49%
ROCE
13.17%
EPS (TTM)
$1.06
Investment Returns
1 Week
-16.97%
1 Month
-5.20%
3 Months
-15.10%
6 Months
-5.72%
9 Months
-18.09%
Financials
Quarterly
All values in $ Mn
745.3
Jun 25
769.0
Sep 25
826.4
Dec 25
759.9
Mar 26
789.6
Jun 26
763.7
Sep 26
Updates
7Nov
Canaccord Genuity lowers Globus Medical price target to $105
Canaccord Genuity lowered Globus Medical's price target to $105. The previous price target was set at $115. Analyst Caitlin Cronin maintained a Buy rating on the stock.
6 days ago
6Nov
Wells Fargo raises Globus Medical price target to $100
Wells Fargo maintains Overweight rating on Globus Medical. Price target raised from $99 to $100 by analyst Larry Biegelsen. Valuation outlook sees a $1 upward revision.
6 days ago
6Nov
BMO Capital downgrades Globus Medical to Market Perform, cuts target
BMO Capital downgrades Globus Medical from Outperform to Market Perform. Price target lowered from $94 to $78 by analyst Vik Chopra. The revision signals a neutral stance on the stock's near-term potential.
6 days ago
6Nov
Globus Medical cuts FY26 revenue guidance to $3.09 billion on Nevro drag
Globus Medical cut FY26 revenue guidance to $3.09 billion from $3.18-$3.22 billion. Q3 adjusted EPS of $1.23 beat consensus by 2.5%, up 4.24% YoY. Q3 sales of $763.7 million missed estimates by 3.62%, down 0.69% YoY. Record free cash flow of $225 million achieved despite higher capex. Board authorized additional $500 million for share repurchases.
7 days ago
13Oct
Globus Medical Q3FY26 Results: Earnings release scheduled for November 5
Globus Medical will release Q3FY26 financial results on November 5, 2026. Conference call scheduled for 4:30 pm Eastern Time following the announcement. Live webcast and telephone dial-in options available for investors.
1mo ago
12Oct
Globus Medical Q2FY26 Results: Non-GAAP EPS up 56% to $1.34
Revenue grew 6% YoY to $789.6 million; base business excluding Nevro grew 9%. Non-GAAP EPS rose 56% YoY to a record $1.34. Adjusted EBITDA margin expanded 740 bps to 35.4%. International revenue increased 18% YoY to $170.5 million. FY26 non-GAAP EPS guidance raised to $4.95-$5.05.
